LOGIN  |  REGISTER
Amneal Pharmaceuticals

InMode to Present at Jefferies Healthcare Conference

May 16, 2024 | Last Trade: US$14.66 0.07 0.48

YOKNEAM, Israel, May 16, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present in-person at the Jefferies Healthcare Conference in New York on June 5, 2024.

The fireside chat, moderated by Matt Taylor, Managing Director, Senior Healthcare Analyst, is scheduled for 7:30 am Eastern Time on Wednesday, June 5 and a live webcast of the presentation can be accessed here. InMode will also hold one-on-one investor meetings in person that same day. To schedule a meeting, please contact your Jefferies representative.

For more information about the event, visit InMode's investor relations site here.

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

Investor Relations Contact:

Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654 

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page